KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Malignant Neoplasm
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 140 (planned)
- Started
- Dec 19, 2025
- Main results expected
- Nov 15, 2029
- Fully finished
- May 31, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants with a Dose Limiting Toxicity (DLT)
Measured over: Up to approximately 21 days
Percentage of Participants who Experience at Least One Adverse Event (AE)
Measured over: Up to approximately 84 months
Percentage of Participants who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 84 months
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 84 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07252739 · record last updated 2026-09-02 · checked 2026-11-09 15:47 UTC